Ouro’s series A was co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners. Monograph Capital participated in the round and also founded the company in partnership with GSK ...

On Friday, San Francisco-based Ouro emerged from stealth revealing $120 million in funding from backers that include GSK, which helped form the young company. “Fundamentally, we think this could ...

Ouro Medicines’ name is short for ouroboros, an ancient symbol of a snake eating itself for eternal recycling, rebirth and renewal. A San Francisco startup, founded by Big Pharma player GSK plc ...

Company founded by Monograph Capital in partnership with GSK; Series A co-led by TPG, NEA, and Norwest SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ...

Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated diseases Skip to main content You ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ... The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by ...

Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information ...

Starting later this year, Ouro intends to start a phase 1 clinical ... with participation from Monograph, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors.